IL1B and Hyperglycemia: In peritoneal macrophage cultures, Iwamoto et al. observed that tofogliflozin modulated hyperglycemia by inhibiting macrophage accumulation and downregulating IL-1β and IL-6 expression, resulting in a significant reduction in atherosclerotic plaque burden.